RxDoctor Payments Data

Joanne Dale, MD

Urology · Nashville, TNNPI 1285860742

Payments from drug & device makers

$1,575in general payments, 2019–2025

Across 66 payments — averaging $23.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$396
  • Rochester Medical Corporation$228
  • Astellas Pharma US Inc$152
  • Endo Pharmaceuticals Inc.$144
  • Urovant Sciences Inc$106
  • Myovant Sciences Inc.$81
  • plus $467 from 18 others

What the payments were for

  • Food & beverage$1,575100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,575 in reported general payments places this provider in the 35th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$120,167
Medicare patients
369
Services billed
1,830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron142$127,126
GemtesaVibegron42$34,632
OrgovyxRelugolix12$33,561
PremarinEstrogens, Conjugated64$27,262
Solifenacin Succinate38$4,497
Tamsulosin Hcl269$3,913
Tadalafil38$3,606
Tolterodine Tartrate ErTolterodine Tartrate23$2,257
Finasteride150$2,022
Estradiol13$1,297
Trospium Chloride22$1,167
Oxybutynin Chloride ErOxybutynin Chloride43$720
Alfuzosin Hcl ErAlfuzosin Hcl22$552
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst32$535
Gentamicin Sulfate36$422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$152$127,126142 claims
PfizerPremarin$12$27,26264 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 276 urology providers in Tennessee.

Other urology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →